Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune
No biopharma company has suffered as many clinical setbacks in Alzheimer’s drug research as Eli Lilly. But that hasn’t stopped the pharma giant from driving back toward the clinic with a deal worth close to $2 billion for a portfolio of preclinical tau aggregation inhibitors.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
